INSULET (GOV MU) stock market data APIs
€284.2124
-1.98(-0.7%)
as of October 22, 2025
Try our APIs with
free plan!
INSULET Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for GOV.MU.
Prev. Close
284.2124
Open
282.2285
High
284.2124
Low
282.2285
52 wk Range
204.9-299.9
Market Cap
16 032 M
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get INSULET data using free add-ons & libraries
Get INSULET Fundamental Data
INSULET Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
INSULET News
New
Stifel resumes coverage on medtech names, sees long-term diabetes devices growth
Investing.com -- Stifel has resumed coverage of several medtech companies, citing steady adoption of continuous glucose monitors (CGMs) and insulin pumps as key drivers for growth. The firm rated Dex...
Insulet Corporation (PODD) Sees Higher 2025–2026 Revenue and Operating Margins, Says Canaccord
Insulet Corporation (NASDAQ:PODD) ranks among the best medical device stocks to invest in. Canaccord Genuity maintained its Buy rating on Insulet Corporation (NASDAQ:PODD) and boosted its price target...
TransMedics Group Stock Earns Relative Strength Rating Upgrade
A Relative Strength Rating upgrade for TransMedics Group shows improving technical performance. Will it continue? Continue Reading View Comments
Insulet (PODD) Valuation: Is There More Room to Run After 22% YTD Gain?
Insulet (PODD) shares are catching attention with a recent daily dip of 1.8%, despite gaining 22% for the year. Investors might be weighing the broader trends in the medical device space as they consi...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
